Acquired hemophilia
Acquired hemophilia
Updated: 08/06/2025
© Jun Wang, MD, PhD
General features
- Rare but potentially life-threatening bleeding disorder
- Associated with autoimmune disorders, solid tumors, hematologic malignancies, dermatologic disorders, inflammatory bowel disease, respiratory diseases, diabetes, acute hepatitis (B and C), severe drug reactions, post-childbirth, or previous usage of coagulation factors
- Bethesda assay can be used to assess the levels of Factor VIII inhibitor
Clinical presentations
- Bleeding
- Hemarthrosis uncommon
Key pathogenesis
- Autoantibodies (inhibitors) directed against plasma coagulation factors
- Most frequently against factor VIII (FVIII)
Key laboratory findings
- Prolonged aPTT NOT reversed on a mixed study
- Reduced FVIII levels
- Positive Bethesda assay
- Normal PT, platelet count
Treatment
- Treat underlying disorder
- Desmopressin in very low titer inhibitors
- High-dose Factor VIII is low titer inhibitors
- Recombinant Factor VIIa for severe bleeding
Back to contents
Comments
Post a Comment